ATG-032

**ATG-032** is an investigational **monoclonal antibody** developed by **Antengene** as a macrophage-regulating immuno-oncology therapy. It targets the inhibitory leukocyte immunoglobulin-like receptor B pathway, with available public descriptions indicating it is an **anti-LILRB antibody** and more specifically an **anti-LILRB2/ILT4 monoclonal antibody** intended for oncology, including solid tumors and hematologic malignancies. The program appeared in Antengene's early-stage internal discovery pipeline and preclinical IND-track portfolio, but the highest publicly reported global development status is **discontinued**.